EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds/defects and epitheliopathies, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body, as well as Eyegate II drug delivery system. The company has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-788-8869
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$410,000.00
Profitability
Miscellaneous
Employees17
OptionableNot Optionable
Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions
What is Eyegate Pharmaceuticals' stock symbol?
Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."
How were Eyegate Pharmaceuticals' earnings last quarter?
Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) announced its quarterly earnings data on Tuesday, November, 13th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.08) by $0.01. The specialty pharmaceutical company earned $0.32 million during the quarter, compared to analysts' expectations of $0.19 million. View Eyegate Pharmaceuticals' Earnings History.
When is Eyegate Pharmaceuticals' next earnings date?
What price target have analysts set for EYEG?
1 Wall Street analysts have issued 1 year price objectives for Eyegate Pharmaceuticals' shares. Their predictions range from $6.00 to $6.00. On average, they expect Eyegate Pharmaceuticals' stock price to reach $6.00 in the next year. This suggests a possible upside of 1,081.1% from the stock's current price. View Analyst Price Targets for Eyegate Pharmaceuticals.
What is the consensus analysts' recommendation for Eyegate Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyegate Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyegate Pharmaceuticals.
Has Eyegate Pharmaceuticals been receiving favorable news coverage?
Media stories about EYEG stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Eyegate Pharmaceuticals earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the next several days.
Are investors shorting Eyegate Pharmaceuticals?
Eyegate Pharmaceuticals saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 498,717 shares, a drop of 41.2% from the December 14th total of 848,269 shares. Based on an average daily trading volume, of 268,160 shares, the short-interest ratio is currently 1.9 days. Currently, 1.5% of the company's stock are short sold. View Eyegate Pharmaceuticals' Current Options Chain.
Who are some of Eyegate Pharmaceuticals' key competitors?
Some companies that are related to Eyegate Pharmaceuticals include Pharmaxis (PXSLY), Tiziana Life Sciences (TLSA), Iterum Therapeutics (ITRM), Humanigen (HGEN), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Alpine Immune Sciences (ALPN), Tetraphase Pharmaceuticals (TTPH), Medicure (MCUJF), Elite Pharmaceuticals (ELTP), Infinity Pharmaceuticals (INFI), CTI BioPharma (CTIC), Aridis Pharmaceuticals (ARDS), Fortress Biotech (FBIO) and Synergy Pharmaceuticals (SGYP).
Who are Eyegate Pharmaceuticals' key executives?
Eyegate Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen From, Pres, CEO & Director (Age 56)
- Dr. Barbara M. Wirostko, Chief Medical Officer (Age 53)
- Mr. Michael P. Manzo, VP of Engineering (Age 60)
- Ms. Sarah Romano, Chief Financial Officer
- Mr. Mike Garanzini, Chief Commercial Officer
When did Eyegate Pharmaceuticals IPO?
(EYEG) raised $5 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 800,000 shares at a price of $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.
Who are Eyegate Pharmaceuticals' major shareholders?
Eyegate Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.16%). Company insiders that own Eyegate Pharmaceuticals stock include Armistice Capital Master Fund, Morton Goldberg, Sarah Romano and Stephen From. View Institutional Ownership Trends for Eyegate Pharmaceuticals.
Which major investors are buying Eyegate Pharmaceuticals stock?
EYEG stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Eyegate Pharmaceuticals stock in the last two years include Armistice Capital Master Fund, Sarah Romano and Stephen From. View Insider Buying and Selling for Eyegate Pharmaceuticals.
How do I buy shares of Eyegate Pharmaceuticals?
Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eyegate Pharmaceuticals' stock price today?
One share of EYEG stock can currently be purchased for approximately $0.5080.
How big of a company is Eyegate Pharmaceuticals?
Eyegate Pharmaceuticals has a market capitalization of $21.07 million and generates $410,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,210,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Eyegate Pharmaceuticals employs 17 workers across the globe.
What is Eyegate Pharmaceuticals' official website?
How can I contact Eyegate Pharmaceuticals?
Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.
MarketBeat Community Rating for Eyegate Pharmaceuticals (NASDAQ EYEG)
MarketBeat's community ratings are surveys of what our community members think about Eyegate Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYEG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEG will underperform the S&P 500 over the long term. You may vote once every thirty days.
